

May 11, 2011

ONO PHARMACEUTICAL CO., LTD.

President and Representative Director: Gyo Sagara

Code No: 4528 at the 1st section of the Tokyo / Osaka Stock Exchange

INQUIRIES: Kinya Morimoto, Managing Director, Corporate Communications

Announcement on Introduction of Corporate Officer System, Changes of Members of the Board of Directors and Appointment of Corporate Officers

Ono Pharmaceutical Co., Ltd. (Osaka, Japan) announced that its Board of Directors meeting held on May 11, 2011 decided the introduction of corporate officer system as well as the following changes of members of the Board of Directors and appointment of Corporate Officers. The changes of members of the Board of Directors and Corporate Auditors will be submitted for approval to the 63rd Annual Shareholders Meeting to be held on June 29, 2011. The introduction of corporate officer system, and changes and appointments of members of the Board of Directors as well as Corporate Officers will be resolved at the Board of Directors meeting to be held following the Annual Shareholders Meeting.

1. Introduction of corporate officer system

1.1 Purpose of the introduction of corporate officer system is:

- (i) to reorganize composition of the Board of Directors and to vitalize and enhance its functions; and
- (ii) by giving Corporate Officers authority to perform business operations under his or her charge, to accelerate the decision making, to improve management efficiency and to enhance the management setup that can timely accommodate changes in management environment.

1.2 Summary of the corporate officer system

- (i) Corporate Officers will be appointed or dismissed by the Board of Directors.
- (ii) A member of the Board of Directors can also be served as a Corporate Officer.
- (iii) The term of Corporate Officers will be one year, and can be reappointed.
- (iv) Specific business operations of a Corporate Officer under his or her charge will be determined by the Board of Directors.
- (v) The system will be composed of Senior Executive Officers, Executive Officers and Corporate Officers.

1.3 The system will be introduced on June 29, 2011.

2. Changes of members of the Board of Directors

2.1 Candidates for members of the Board of Directors (as of June 29, 2011)

New Position	Name	Current Position
President, Representative Director, and Chief Executive Officer	Gyo Sagara	President, Representative Director, and Chief Executive Officer
Member of the Board of Directors Senior Executive Officer Executive Director, Clinical Development	Hiroshi Awata	Senior Managing Director, Director of Development Headquarters
Member of the Board of Directors Executive Officer Executive Director, Discovery and Research	Kazuhito Kawabata, Ph.D.	Managing Director, Director of Research Headquarters
Member of the Board of Directors Executive Officer Executive Director, Sales and Marketing	Shinji Fujiyoshi	Managing Director, Director of Marketing Headquarters
Member of the Board of Directors Executive Officer Executive Director, Corporate Management*	Kei Sano	Corporate Auditor (full time)
Member of the Board of Directors Corporate Officer Director, Environment Management	Isao Ono	Executive Director, Director of Environment Management
Member of the Board of Directors Corporate Officer Vice Executive Director, Sales and Marketing	Fumio Takahashi	Executive Director, Deputy Director of Marketing Headquarters
Member of the Board of Directors Corporate Officer Director, Tsukuba Research Institute and Advanced Medicinal Research	Daikichi Fukushima, Ph.D.	Executive Director, Director of Tsukuba Research Institute and Advanced Medicinal Research

* Corporate Management is newly established on June 29, 2011.

2.2 Resigning members of the Board of Directors

- Kinya Morimoto, Managing Director, Director, Corporate Communications
(He will serve as Executive Officer, Director, Corporate Communications.)
- Hiroshi Ichikawa, Executive Director, Senior Director, Marketing Strategy Planning
(He will serve as Corporate Officer, Senior Director, Marketing Strategy Planning.)
- Naonobu Endo, Executive Director, Director, Production and Distribution Headquarters
(He will serve as Director, Fujiyama Plant.)
- Shozo Matsuoka, Executive Director, Chairman and President, Ono Pharma USA, Inc.
(He will serve as Corporate Officer, Director, R&D Strategy Planning **.)

** R&D Strategy Planning is newly established under the direct supervision of President on June 29, 2011.

2.3 Candidates for Corporate Auditors

New Position	Name	Current Position
Corporate Auditor (full time)	Shigeo Shimada	Corporate Auditor (Full time)
Corporate Auditor (full time)	Katsuyoshi Nishimura	Director, Research Administration
Corporate Auditor	Yasuo Araki ***	Corporate Auditor

*** Yasuo Araki is a candidate for an Outside Corporate Auditor.

2.4 Resigning Corporate Auditors as of June 29, 2011

- Kei Sano, Corporate Auditor (full time)

3. Appointment of Corporate Officers (as of June 29, 2011)

- Hiroshi Awata, Senior Executive Officer, Executive Director, Clinical Development (Member of the Board of Directors)
- Kazuhito Kawabata, Executive Officer, Executive Director, Discovery and Research (Member of the Board of Directors)
- Shinji Fujiyoshi, Executive Officer, Executive Director, Sales and Marketing (Member of the Board of Directors)
- Kei Sano, Executive Officer, Executive Director, Corporate Management (Member of the Board of Directors)
- Kinya Morimoto, Executive Officer, Director, Corporate Communications
- Isao Ono, Corporate Officer, Director, Environment Management (Member of the Board of Directors)
- Fumio Takahashi, Corporate Officer, Vice Executive Director, Sales and Marketing (Member of the Board of Directors)
- Daikichi Fukushima, Corporate Officer, Director, Tsukuba Research Institute and Advanced Medicinal Research (Member of the Board of Directors)
- Shozo Matsuoka, Corporate Officer, Director, R&D Strategy Planning
- Hiroshi Ichikawa, Corporate Officer, Director, Marketing Strategy Planning
- Michio Tezuka, Corporate Officer, Director, External Affairs
- Shinpei Futami, Corporate Officer, Director, Tokyo First Branch
- Toichi Takino, Corporate Officer, Head of Global Business Development and Licensing, and Executive Vice President, Ono Pharma USA, Inc.